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An estimated one-third of the world population is latently
infected with Mycobacterium tuberculosis. These nonreplicat-
ing, dormant bacilli are tolerant to conventional anti-tubercu-
losis drugs, such as isoniazid. We recently identified di-
arylquinoline R207910 (also called TMC207) as an inhibitor of
ATP synthase with a remarkable activity against replicating
mycobacteria. In the present study, we show that R207910 kills
dormant bacilli as effectively as aerobically grown bacilli with
the same target specificity. Despite a transcriptional down-reg-
ulation of the ATP synthase operon and significantly lower cel-
lularATP levels, we show that dormantmycobacteria dopossess
residual ATP synthase enzymatic activity. This activity is
blocked by nanomolar concentrations of R207910, thereby fur-
ther reducingATP levels and causing a pronounced bactericidal
effect. We conclude that this residual ATP synthase activity is
indispensable for the survival of dormantmycobacteria,making
it a promising drug target to tackle dormant infections. The
unique dual bactericidal activity of diarylquinolines on dormant
as well as replicating bacterial subpopulations distinguishes
them entirely from the current anti-tuberculosis drugs and
underlines the potential of R207910 to shorten tuberculosis
treatment.
Mycobacterium tuberculosis infection results in more than 2
million deaths per year and is the leading cause of mortality in
people infected with HIV2 (1). The global epidemic of tubercu-
losis (TB) is fuelled by co-infection of HIV patients with TB and
a rise inmultidrug-resistant TB strains (2). Despite the fact that
TB control programs have been in place for decades, approxi-
mately one-third of the world population is latently infected
with M. tuberculosis. Reactivation of latent TB is a high risk
factor for disease development, particularly in immunocom-
promised individuals, such as HIV-infected patients. For global
control of the TB epidemic, there is an urgent medical need for
new drugs active against dormant or latent bacilli. These so-
called sterilizing drugs would be able to shorten the current
6-month treatment duration for drug-susceptible TB and also
offer new treatment opportunities for latent TB.
Tubercle bacilli enter lungs of healthy individuals by inhala-
tion, where they are phagocytosed by the alveolar macrophages
that eliminatemost of the invadingmycobacteria (3). However,
a small proportion of bacilli survive and exist in a nonreplicat-
ing, hypometabolic state, and these bacilli are tolerant to killing
by bactericidal anti-TB drugs, such as isoniazid (4). They can
linger in these altered physiological environments for an
individual’s lifetime and maintain the capability of causing
active TB after reactivation. The pathophysiological condi-
tions in human lesions, thought to lead to persistence, are
reduced oxygen tension, nutrient limitation, and acidic pH
(5, 6).
Recently, we identified a newchemical class, diarylquinolines
(DARQs) that demonstrate potent anti-mycobacterial activity
on replicating bacilli both in vitro and in vivo (7), and the lead
compound, R207910 (or TMC207), is currently in Phase IIb
clinical trials for the treatment of patients with multidrug-re-
sistant TB. R207910 acts by specifically targeting the mem-
brane-bound c-subunit of F1F0-ATP synthase, the ATP-syn-
thesizingmachinery of the cell (8). During synthesis of ATP, the
energy stored in the electrochemical proton gradient across the
membrane is utilized to drive protons from the periplasmic
space into the cytoplasm through the F0 subunit and supplying
a torque to the F1 unit to convert ADP into ATP (9, 10). Under
nonrespiratory conditions, in several bacteria, ATP synthases
can function in the reverse direction, hydrolyzing ATP to ADP
throughATPase activity and as such pumping protons from the
cytoplasm into the periplasmic space (11). In this way, ATP
synthase generates the membrane potential required for the
uptake of nutrients. In dormant mycobacteria, a considerable
remodeling of the respiratory chain has been reported, includ-
ing down-regulation of cytochrome aa3 type oxidase and up-
regulation of the cytochrome bd typemenaquinole oxidase (12,
13). Several studies also suggest that hypometabolic, nonrepli-
catingmycobacteria have decreased requirements forATP syn-
thase, since the genes encoding the components of the ATP
synthase operon are down-regulated, both in vitro and in vivo
(12–14). It is, however, an open question whether ATP syn-
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thase plays an essential role in dormant bacilli and whether the
enzyme is responsible forATP synthesis and/ormaintenance of
themembrane potential. Furthermore, it is not knownwhether,
despite ATP synthase down-regulation, this enzyme can still be
utilized as a drug target in dormant bacilli and whether DARQs
are still able to effectively kill dormant bacilli.
Here we report that, despite a substantial down-regulation of
the ATP synthase operon and reduced cellular ATP levels,
DARQs effectively kill nonreplicatingM. tuberculosis.We find
that dormant mycobacteria have active and functional ATP
synthase that is capable of synthesizing ATP, a scarce energy
resource in a nonreplicating cell. The depletion of ATP in dor-
mantmycobacteria by the R207910-mediated chemical inhibi-
tion of ATP synthase leads to potent bactericidal activity. Thus,
targeting processes that generate ATP and concurrently dis-
turb the cellular ATP homeostasis is an effective strategy
against dormancy. R207910 exhibits no significant effect on the
membrane potential in dormant or replicating mycobacteria,
suggesting that ATP synthase is not critical for maintaining the
membrane potential but is primarily used for the production of
ATP.
We also demonstrate an increased susceptibility of dormant
mycobacteria toward R207910 as comparedwith actively grow-
ing bacteria. Using R207910-resistantmycobacterial strains, we
show that the drug specifically targets ATP synthase during
dormancy. The unique dual bactericidal action of R207910 on
dormant as well as actively replicating bacteria probably con-
tributes to its remarkable sterilizing efficacy in mice, where
R207910 as a monotherapy was shown to be as effective as the
triple combination of rifampin, isoniazid, and pyrazinamide (7,
15). Thismay also explain the ability of this drug to render lungs
of infected mice culture-negative faster than first line anti-TB
drugs.
In conclusion, despite a number of changes in the energy
metabolism during dormancy, the ATP production by ATP
synthase remains essential for mycobacterial survival. The cur-
rent study demonstrates the critical importance of ATP syn-
thase in mycobacterial dormancy and suggests that the ATP
synthase is an excellent target to treat latent TB infections.
EXPERIMENTAL PROCEDURES
Bacterial Strains and Culture Medium—M. tuberculosis
H37Rv, Mycobacterium smegmatis, and Mycobacterium bovis
BCG were obtained from the American Type Tissue Culture
collection. Mycobacteria were cultured in Middlebrook 7H9
medium (Difco) with 0.05% Tween-80 (Sigma) in log phase for
a period of 3–4 days before the start of the experiment. The
incubation was done in a 250-ml sterile Duran bottle with stir-
ring conditions 37 °C (500 rpm).
Chemical Synthesis of DARQ Analogs—DARQ compounds
are synthesized as described in a earlier patent (WO2004/
011436) and previous reports (7).
MIC Microdilution Assays and Determination of Minimum
Bactericidal Concentration (MBC90) andWayne Cidal Concen-
tration (WCC90)—Minimum inhibitory concentration (MIC,
g/ml) of M. tuberculosis against several DARQ compounds
was determined by using 7H9 liquid broth and 7H10 agar dilu-
tion as described in earlier studies (16) with minor modifica-
tions using Alamar blue or resazurin for fluorometric measure-
ment (7). MBC90 (g/ml) was determined as the concentration
where 90% of the aerobic grown bacteria were killed after 5 days
of treatment by colony-forming unit (CFU) counting using
7H10 agar dilution according to Clinical and Laboratory Stand-
ards Institute guidelines. WCC90 (g/ml) was determined as
the concentrationwhere 90%of the dormant bacteria (grown in
theWaynemodel) were killed after 5 days of treatment by CFU
counting using 7H10 agar dilution.
Dormancy Assays—Drastic oxygen depletion (hypoxia
model) of mycobacterial cultures was achieved by placing
loosely capped tubes containing different drug concentrations
inside an anaerobic jar (BBL) along with anaerobic gas genera-
tion envelopes (using palladium catalysts), as described previ-
ously (17). After 7 days of anaerobiosis, the dormant cultures
were harvested by low speed centrifugation, washed twice with
7H9 medium to remove the drugs, and resuspended in drug-
free medium. The CFUs of the treated and untreated cultures
were determined by plating on 7H10 agar to evaluate the bac-
tericidal activity. In the Wayne model, gradual O2 depletion
induces dormancy in mycobacterial cultures, as previously
described (18). Briefly, after induction of dormancy for 18 days
by gradual O2 depletion, cultures without exposure to oxygen
were treated further with various drug concentrations for a
period ranging from 4 to 21 days, and CFUs were counted on
7H10 plates. In theNOmodel, dormancywas obtained by incu-
bating cultures with 150 M of a NO donor (diethylenetri-
amine/nitric oxide (DETA/NO)) for 2 h, followed by treatment
with several compounds for 10 h as previously described (19).
RNA Isolation and Real Time Quantitative PCR—Dormant
and aerobically grown bacterial pellets were resuspended in
Trizol and disrupted with acid-washed glass beads in theMixer
Mill (MM301). Total RNAwas isolated as previously described
(20) and cleaned up with the RNeasy Protect Bacteria minikit
(QIAgen). Reverse transcription was carried out from 0.5 g
of total RNA using random hexamer primers and Super-
script II RT as described by the manufacturer (Invitrogen).
The sequence of the TaqMan FAM (6-carboxyfluorescein)
and TAMRA (6-carboxy-N,N,N,N-tetramethylrhodamine)
probes (Eurogentec) and primers for the mycobacterial genes
analyzed in this study are available upon request. Real time
quantitative PCRwas carried out using theABI PRISM7900HT
sequence detection system (Applied Biosystems) as described
by themanufacturer. Amplification of endogenous 16 S riboso-
mal RNA was performed to standardize the amount of cDNA
sample added to each reaction.
Total Cellular ATP Measurement Assay—ATP levels of log
phase aerobic and dormant cultures of M. tuberculosis were
measured using the ATP bioluminescence assay kit (Roche
Applied Science), as previously described (8). ATP levels were
followed during dormancy (Wayne model) from day 0 to day
21. Additionally, M. tuberculosis cultivated under Wayne dor-
mancy conditions for 18 days were treated with R207910
(0.006–6 g/ml), isoniazid (0.3 g/ml), and dicyclohexylcar-
bodiimide (DCCD) (100g/ml) for 4 days, andATP levels were
measured.
Measurement of ATP Synthesis Activity—ATP synthesis of
dormant M. smegmatis grown under Wayne conditions for 10
R207910 or TMC207 and DormantMycobacteria
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days wasmeasured as described previously (8). Briefly, inverted
membrane vesicles were prepared using a precooled French
pressure cell at 20,000 p.s.i. The membrane vesicles were pre-
incubated with R207910 or DCCD under stirring conditions at
room temperature for 10 min. The ATP synthesis activity was
determined by energizing the membranes with NADH and
quantifying the amount of ATP produced using the luciferin/
luciferase system (ATP Bioluminescence Assay Kit HS II;
Roche Applied Science). Data are presented as averages S.E.
Measurement of the Membrane Potential—Membrane
potential was measured using tetra-[3H]phenylphosphonium
bromide (Amersham Biosciences) in aerobic and Wayne dor-
mant (10 days) M. smegmatis, as previously described (21).
Briefly, cells were energizedwith 20mMglucose, tetra-[3H]phe-
nylphosphonium bromide was added, and cells were centri-
fuged through silicon oil. Supernatant and cell pellet were dis-
solved in scintillation fluid and counted with a liquid
scintillation analyzer (TRI-CARB 2100TR; Packard). Mem-
brane potential (in mV) was calculated according to the Nernst
relationship. Values represent averages  S.E. of four inde-
pendent experiments. Comparisons were performed using Stu-
dent’s t test (StatXact). p values of 0.05 were considered as
statistically significant.
RESULTS
Bactericidal Activity of R207910 on DormantM. tuberculosis—
The effect of DARQ lead compound, R207910, on the growth of
nonreplicating M. tuberculosis was tested in three different in
vitro dormancy models. As a control for target specificity dur-
ing dormant conditions, we tested the efficacy of R207910 on
the R207910-resistant strain of M. tuberculosis (BK12), carry-
ing a point mutation in the -helix of the c-subunit of the ATP
synthase complex (7). Both wild type and mutant strains were
subjected to dormancy using either gradual (Wayne) or drastic
(hypoxia) O2 depletion or NO treatment in the presence of 0.1
and 10 g/ml R207910 (Fig. 1).
We treated Wayne dormant M. tuberculosis for 7 days with
R207910 to determine its killing efficacy. As can be seen in Fig.
1A, R207910 at 10 g/ml leads to a 1.8-log10 reduction in CFU
counts, whereas no apparent effect was observed at 0.1 g/ml.
The viability of dormant bacilli was not affected by isoniazid
treatment, an inhibitor of biosynthesis of cell wall mycolic
acids. In contrast, metronidazole at 100g/ml led to a 1.9-log10
reduction in CFUs as compared with untreated control. Met-
ronidazole is a prodrug that is effective only under anaerobic
conditions.However, it has been shown to be ineffective against
latent mycobacteria in a Cornell mouse infection model (22).
DCCD, a nonspecific ATP synthase inhibitor, showed a drastic
killing effect at 100 g/ml (Fig. 1A).
In the hypoxia model, M. tuberculosis cultures were sub-
jected to drastic O2 depletion in an anaerobic chamber.
R207910 reduced the mycobacterial viability by 2.1-log10 CFUs
at 10 g/ml but had no apparent effect at 0.1 g/ml (Fig. 1B).
Metronidazole tends to be slightly more potent than in the
Wayne model, leading to a 2.5-log10 CFU reduction at 100
g/ml. This can be explained by the extreme hypoxic condi-
tions created in the anaerobic chamber, and as such, the effects
of metronidazole, which works best in a severely O2-depleted
environment, tend to be enhanced.
NO has been shown to inhibit aerobic respiration in several
bacterial systems, and it induces a dormancy response inmyco-
bacteria similar to oxygen depletion (19). Treatment of midlog
FIGURE 1. Effect of R207910 on wild type and resistant BK12M. tubercu-
losis grown under oxygen depletion or NO stress. A,M. tuberculosis were
grown under gradual O2 depletion (Waynemodel) for 18 days to induce dor-
mancy, followed by treatment with different compounds for 4 days. B, killing
of M. tuberculosis by R207910 under hypoxia growth conditions. The killing
was measured after 7 days. C, killing by R207910 of NO-induced dormantM.
tuberculosis. Dormancywas inducedby a 2-h treatmentwith 150MofDETA/
NO. The killing was measured after 10 h.
R207910 or TMC207 and DormantMycobacteria
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aerobically grown cultures ofM. tuberculosiswith low nontoxic
concentrations (150 M) of DETA/NO induced typical dor-
mancy regulon gene expression (Fig. 3A). In our study, 2 h after
treatmentwithDETA/NO,mycobacteriawere exposed for 10 h
to R207910 and control drugs. DETA/NO alone had no effect
on mycobacterial survival as compared with untreated control
(Fig. 1C). Furthermore, isoniazid (10 g/ml) had no effect on
these dormant bacilli, whereas the viability of the bacilli was
drastically reduced by DCCD. However, metronidazole (100
g/ml), in contrast to the O2 depletion dormancy assays, was
not bactericidal, because as a prodrug, it is active only in an
O2-limiting and not in an NO environment. R207910 (10
g/ml) led to a 1-log10 drop in CFU counts, whereas no appar-
ent effect was observed at 0.1 g/ml. It has been previously
shown that NO dissipates in the reaction tubes over a period of
time, and by 16 h, the bacteria tend to lose their dormant phe-
notype (19). However, the effects of R207910 on NO-treated
mycobacteria in this model (10 h of treatment) were reached
within the dormant physiological phase.
Susceptibility Comparison of Dormant and Aerobically
GrownMycobacteria with R207910—The present first line and
second lineTBantibiotics exhibit strong bactericidal activity on
replicatingmycobacteria, but none of them show a comparable
efficacy on dormant bacilli. In order to evaluate the bactericidal
activity of R207910 on dormant versus actively replicating
mycobacteria, we determined the bactericidal concentration of
R207910 in aerobic (MBC90) andWayne dormant (WCC90)M.
tuberculosis (Table 1). Rifampicin and isoniazid, included as
controls, were both more potent in aerobically grown and sig-
nificantly less for the dormant bacilli. In contrast, R207910 was
slightly more active on dormant bacilli (WCC90 of 1 g/ml), as
compared with aerobically grown bacilli (MBC90 of 2 g/ml).
This suggests that dormant bacteria are slightly more prone
(about 2-fold) to R207910 bactericidal activity as compared
with actively growing mycobacteria (WCC90/MBC90 ratio of
0.5).
To further evaluate this result, we measured killing kinetics
of R207910 and isoniazid on Wayne dormant and aerobically
grown bacilli (Fig. 2). For this purpose, both cultures were
diluted to equalA600 values or107 to 108 CFU/ml and treated
with R207910 (10 g/ml). For aerobic cultures, we observed an
initial 2.2-log10 drop in CFUs by the end of the first week of
treatment with R207910 and an additional 0.8-log10 reduction
in CFUs by day 14. In contrast, treatment of dormantmycobac-
teria resulted in an initial 1.8-log10 drop in CFUs by the end of
the first week, but by day 14, killing wasmore pronounced, with
an additional 3.0-log10 drop in CFUs versus untreated control.
As expected, isoniazid had no effect on dormant bacterial cul-
tures. However, in aerobic cultures, isoniazid killed about 2.2
log10 during the first week, with no additional killing during the
second week.
R207910-mediated killing of dormant bacilli at a 10 g/ml
concentration was highly potent, since no bacteria could be
counted by day 14 (Fig. 2). In contrast, the killing kinetics of
R207910 at 1 g/ml on Wayne dormant M. tuberculosis sug-
gested a characteristic biphasic killing with a 2.9-log10 drop in
CFUs by day 14 and no further reduction by day 21 (Fig. S1).
In summary, bymeasuring the bactericidal concentrations as
well as killing kinetics, we demonstrated that R207910 kills dor-
mantM. tuberculosis at least as effectively as actively replicating
bacilli. This makes R207910 the only TB drug with equal bac-
tericidal activities on different bacterial subpopulations.
Specificity ofDARQActivity inDormantMycobacteria—Tar-
get specificity of DARQs was assessed by introducing chemical
changes in the DARQ scaffold. During dormancy, bacteria
might have alternativemeans of energy or ATP production (e.g.
substrate level phosphorylation), and as such, ATP synthase
might be redundant. Hence, it is postulated that R207910might
affect other cellular targets as well (23). At first, we studied the
correlation between various structural and chemical changes in
R207910 and its analogs versus their effect on biological activity.
This leads to the determination of a structure-activity relation-
ship. Over 400 DARQ derivatives were prepared and tested on
actively replicating and aerobically grown M. tuberculosis cul-
tures in in vitro MIC determination assays (data not shown).
Five compounds (Fig. S2A) with MICs between 0.09 and 20
g/ml were selected for evaluating their bactericidal effect on
Wayne dormantM. tuberculosis. R207910 at 1 and 10g/ml led
to 1.3- and 2.1-log10 CFU reduction, respectively, as compared
with untreated dormant control cultures (Table 2). As can be
seen in Table 2, an analogue with a methyl substituent on the
first aryl moiety of R207910 (named 18040971-AAA) retained
FIGURE 2. Comparative R207910 killing kinetics for aerobically grown
anddormantM. tuberculosis.R207910was tested against dormant (Wayne)
and aerobically grown cultures of M. tuberculosis. The dormant and aerobic
cultures, with equal start A600 values or comparable starting CFUs (10
7 to 108
CFU/ml), were treated with 10 g/ml R207910 or 10 g/ml isoniazid. Killing
wasmonitored bymeasuring CFU/ml after 1, 4, 7, and 14 days on 7H10 plates
and plotted as log10 CFU reduction, calculated against nontreated controls.
Note that for dormant mycobacteria treated with R207910 (10 g/ml), the
CFU counts were below the detection limit at 14 days (102 CFU/ml).
TABLE 1
Comparative killing activity of TB compounds (rifampicin, isoniazid,
and R207910) for actively replicating and dormantM. tuberculosis
Killing is represented as MBC90 for actively replicating and WCC90 for dormant
bacilli. TheWCC90/MBC90 ratio reflects the comparative killing efficiency. R207910
is slightly more potent toward dormant bacteria with a lowWCC90/MBC90 ratio as
compared with rifampicin and isonazid. Isoniazid has no detectable activity on
dormant bacteria, and rifampicin is significantly less active on dormant as compared
to actively replicating bacilli.
Compound MBC90 WCC90 WCC90/MBC90
g/ml g/ml
Rifampicin 0.03 0.5 17
Isoniazid 0.25 64 256
R207910 2 1 0.5
R207910 or TMC207 and DormantMycobacteria
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its bactericidal activity on dormant bacteriawith 1.55-log10 kill-
ing at 1 g/ml. However, replacement of the dimethylamino
group by azole groups (25756770-AAA) led to a decrease in the
activity on both aerobic (MIC 8.19 g/ml) and dormant bacilli
(0.29-log10 CFU reduction). Interestingly, changing the chain
length in R207910 between the hydroxyl and the terminal di-
methylamino group (18086601-AAA) also decreased activity
on both aerobic (MIC 20.21 g/ml) as well as dormant bacilli
(0.11-log10 CFU reduction). These data suggest a strong corre-
lation between structural variations of the DARQ scaffold and
the subsequent effect on their activities against replicating and
dormant bacilli (Fig. S2B). The sharp overlap between the bac-
tericidal activities ofDARQanalogs ondormant and replicating
bacilli implies that their effects are highly target-specific, irre-
spective of mycobacterial growth conditions and physiological
states.
In a second approach to characterize the target specificity of
R207910 during dormancy, we tested the efficacy of R207910
on the resistant strain of M. tuberculosis (BK12) bearing a
mutation in c-subunit of ATP synthase (7). At the highest con-
centration of 10 g/ml, R207910 had no effect on this mutant
strain in Wayne (Fig. 1A), hypoxia (Fig. 1B), and NO (Fig. 1C)
conditions. Isoniazid had no effect under these conditions, sug-
gesting that bacilli were indeed in a nonreplicating state. The
ATP synthase inhibitor DCCD had a drastic killing effect and
led to a 5.3-, 2.8-, and 4.3-log10 drop in CFUs in Wayne (Fig.
1A), hypoxia (Fig. 1B), and NO (Fig. 1C), respectively. The lack
of cross-resistance between these two compounds suggests that
although DCCD binds to the same target as R207910, its bind-
ing pocket is different. In summary, our results demonstrate
that killing ofmycobacteria byDARQs critically depends on the
structure of the DARQ compound as well as critical amino acid
compositions in the target protein.
ATP Synthesis in Nonreplicating Mycobacteria—The dor-
mancy physiological phase involves changes in several meta-
bolic pathways that lead to the transcriptional reprogramming
of different bacterial genes. In a first step, we confirmed tran-
scriptional up-regulation of the dormancy regulon in the three
dormancy models, as previously reported (12–14). We
explored the effect of dormancy on the ATP synthase operon
under O2 depletion and NO stress conditions by real time
quantitative PCR for atpA to atpH. InM. tuberculosis, the ATP
synthase consists of a transmembrane F0 and a cytosolic F1
subunit. F0 is composed of Rv1304 (atpB), Rv1305 (atpE), and
Rv1306 (atpF), whereas the F1 subunit is composed of Rv1308
(atpA), Rv1311 (atpC), Rv1310 (atpD), Rv1309 (atpG), and
Rv1307 (atpH). The transcriptional response of atpA to -Hwas
significantly down-regulated in both the hypoxic and the
Wayne dormancy models (Fig. 3A). However, in NO-treated
samples, there was no apparent change in levels of ATP syn-
thase mRNA transcripts. This differencemight be explained by
the briefNOexposure time (2 h, comparedwith several days for
Wayne and hypoxia). However, both O2-depleted and
NO-treated cultures showed up-regulation of five characteris-
tic dormancy marker genes (Rv2623, Rv2626, Rv2007, Rv2031,
and Rv3130), suggesting that indeed a dormant physiological
state was triggered upon exposure to NO or O2 stress (Fig. 3A)
(19, 20).
In order to evaluate the effect of down-regulation of ATP
synthase in dormant bacteria, we measured ATP levels in M.
tuberculosis in Wayne conditions over a period of 21 days (Fig.
3B). As shown upon O2 depletion, a significant decrease in the
amount ofATPwas observed at day 1with additional decline by
day 14. Similarly, ATP levels in Wayne dormantM. smegmatis
were significantly reduced compared with actively growing
bacilli (data not shown). At the corresponding time points,
these dormant cultures were also analyzed for atpE mRNA
expression. As can be seen in Fig. 3B, decreased atpE mRNA
transcription at each time point correlates highly with lower
ATP levels.
As compared with actively replicating bacilli, there is more
than 90% decrease in ATP levels in dormant M. tuberculosis
(Fig. 3B, inset). Thus, total cellular ATP levels in dormant
mycobacteria are significantly lower compared with replicating
bacteria. We subsequently analyzed whether R207910 further
decreases the cellular ATP levels in Wayne dormantM. tuber-
culosis. As can be seen in Fig. 3C, treatment of dormant myco-
bacteria with R207910 at 0.06 g/ml (1 MIC) results in a
significant decrease in ATP levels as compared with untreated
controls. Isoniazid (0.3 g/ml) had no effect on ATP levels,
whereas DCCD (100 g/ml) drastically reduced ATP levels.
This suggests that R207910, even at a low concentration (1
MIC), is highly effective in reducing ATP levels in dormant
bacteria. This demonstrates high susceptibility of dormant
mycobacteria to lower concentrations of R207910.
This increased susceptibility is observed despite a transcrip-
tional down-regulation of theATP synthase operon. In order to
show that ATP synthase still has the residual functional activity
during dormancy, we measured synthesis of ATP by the ATP
synthase enzyme in membrane vesicles isolated from dormant
M. smegmatis. This ATP synthase activity was completely
blocked by R207910 in a dose-dependent manner with an IC50
of around 1.5 ng/ml (Fig. 4A). These results indicate that in
dormant mycobacteria, ATP synthase still shows a residual
function, despite overall transcriptional down-regulation and
other changes in energy metabolic pathways.
TheATP synthase enzyme complex canhave a bimodal func-
tion: synthesis of ATP and generation of amembrane potential.
TABLE 2
Bactericidal action of DARQs in killing aerobic and dormantM.
tuberculosis
Different DARQ analogs were tested on M. tuberculosis cultures grown in aerobic
conditions or in the Wayne oxygen depletion model. MIC90 values on aerobically
grown bacilli were compared with the bactericidal activity (log10 reduction asmeas-
ured against untreated control) on dormant bacteria in 7H10 agar. The bactericidal
activity was evaluated at concentrations of 1 and 10g/ml. Each value is themean of
aminimumof two different experimental values, and each experiment was repeated
at least two times. A strong correlation between structural variations of DARQs
analogs and their biological effects against replicating and dormant bacilli is
observed.
Compound ID MIC90(aerobic cultures)
Log10 reduction
(dormant cultures)
10 g/ml 1 g/ml
g/ml
R207910 0.09 2.1 1.35
18040971-AAA 0.16 2.13 1.55
17996134-AAA 1.74 1.14 0.87
25756770-AAA 8.19 0.98 0.29
18086601-AAA 20.21 0.23 0.11
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Despite the low ATP levels and a reduced expression of ATP
synthase, dormant bacteria still need to maintain a membrane
potential for cellular viability. We tested the effect of R207910
on membrane potential of Wayne dormant M. smegmatis. It
was seen that dormant bacilli are able to maintain an energized
membrane ormembrane potential (135mV), albeit at slightly
lower levels compared with aerobically grown bacilli (180
mV) (p  0.001) (Fig. 4B). The presence of R207910 had no
significant effect on this membrane potential both in aerobic
and in dormantM. smegmatis (data not shown). This suggests
that ATP synthase is not required for the generation of the
membrane potential by pumping protons in the periplasm.
Taken together, dormantmycobacteria have functional ATP
synthase: low but critically needed ATP levels and an energized
membrane. Hence, dormant bacteria are not metabolically or
physiologically inert but still operate some key cellular
processes.
DISCUSSION
Treatment of active TB in humans by a regimen combining
four drugs (isoniazid, rifampicin, pyrazinamide, and ethambu-
tol) leads to rapid killing of the bacteria in the sputum during
the first 2months (24). However, relapses occur if the therapy is
not continued further for 4months to kill the remaining bacilli.
These bacilli are likely to be located in caseous regions with
limited supply of O2 and nutrients and exhibit a dormant phe-
notype. Penetration of drugs into these microenvironments
tends to be restricted, and these bacteria seem to be tolerant to
antimycobacterial drugs, such as isoniazid (25). Therefore,
there is an urgent need for the development of new drugs that
specifically target dormant bacilli.
Our study demonstrates that DARQ lead compound
R207910 effectively killed dormant mycobacteria in all three in
vitro dormancy model systems used that mimic the microenvi-
ronment encountered by mycobacteria within granulomas in
humans. Surprisingly, we observed a higher susceptibility of
dormant bacilli to DARQs as compared with aerobically grown
cultures, a unique property that distinguishes R207910 from
presently used first and second line anti-TB drugs, such as
rifampicin (WCC90/MBC90 of 17). This dual action of DARQs
might explain why the combination of R207910 with the stand-
ard of care regimen (rifampin, isoniazid, and pyrazinamide) led
to a 50% faster reduction of CFU counts than the control regi-
men (7, 15). The sterilizing efficacy of R207910 in mice, involv-
ing measurement of relapse rates 3 months after cessation of
treatment, demonstrated that R207910 reduces the number of
relapses compared with the standard of care combination ther-
apy (26). Moreover, treatment of Guinea pigs with R207910
resulted in an almost complete eradication of M. tuberculosis
throughout both primary and secondary lesions in the lung
granulomas after 6 weeks of treatment (27).
In correlation with transcriptional down-regulation of ATP
synthase, the ATP levels are also significantly decreased in dor-
mant mycobacteria, suggesting an energy adaptation for this
new physiological state. It has already been suggested that
mycobacterial isolates from human lesions use alternative
energy pathways, since several genes responsible for the lipid
metabolism are up-regulated (28). Considering the bactericidal
action of R207910 on dormant M. tuberculosis, it is likely that
nonreplicating mycobacteria still need minimal amounts of
ATP to survive, provided by a residual activity of ATP synthase.
This suggests that dormantmycobacteria can bemore prone to
alterations in cellular ATP pools due to inhibition of ATP syn-
thase as compared with actively growing bacilli. Our data thus
provide a nice example of a down-regulated enzyme acting as a
highly efficient target, whereas generally enzymes that are up-
regulated during dormancy were considered to be promising
targets for latent TB.
FIGURE 3. Decreased requirement of ATP synthesis in nonreplicating mycobacteria. A, real time quantitative PCR (RT-qPCR) was performed on cDNA
generated from total RNA extracted fromM. tuberculosis exposed to various dormancy conditions. The change in gene expression was calculated by normal-
izingCT values of individual gene transcripts againstCT values of 16 S rRNA. Normalized valueswere comparedwith control values fromM. tuberculosis cultures
grownunder aerobic conditions, and -fold changewas calculated. Eachvalue is themeanof twodifferent experimentswith S.D. of less than10%.B, intracellular
ATP levels and atpE mRNA expression in M. tuberculosis at different time points (up to 21 days) in Wayne O2 depletion conditions. The inset represents the
differences in ATP levels (nmol/mg) of dormantM. tuberculosis comparedwith aerobic culture. C, effect of treatment of R207910, isoniazid, and DCCD (4 days)
on ATP levels inM. tuberculosis cultivated under Wayne dormancy conditions for 18 days.
FIGURE 4. ATP synthase is functional in dormant M. smegmatis. A, ATP
synthesis activity in invertedmembrane vesicles (50g/ml) fromdormantM.
smegmatis cultured for 10 days under Wayne O2 depletion conditions. Posi-
tive control was membrane vesicles with buffer containing ADP, Pi, and
NADH, whereas negative control excluded NADH and Pi from the assay
buffer. B, effect of R207910 onmembrane potential in dormantM. smegmatis
cultured for 10 days under Wayne O2 depletion conditions. The membrane
potential was measured using tetra-[3H]phenylphosphonium bromide.
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For dormant mycobacteria, a role for ATP synthase in syn-
thesizing ATP and/or maintaining the membrane potential (by
hydrolyzing ATP and pumping protons across the membrane)
has been proposed (29). DARQs potently inhibited ATP syn-
thesis activity but even at high concentrations had no signifi-
cant effect on the membrane potential. This is further sup-
ported by the previous finding that the purifiedATP synthase of
Mycobacterium phlei appears to have only very low or latent
ATP hydrolysis activity (30). It has been suggested that for
restoring the redox balance and proton motive force during
dormant conditions, the nitrate reductase complex, an alterna-
tive respiratory enzyme, can generate a proton motive force
during dormant growth conditions (31). Furthermore, under
low O2 conditions, there are several changes in the respiratory
chain complexes in mycobacteria, including up-regulation of
cytochrome bd-typemenaquinol oxidase that has a higher oxy-
gen affinity and a non-proton-translocating NADH dehydro-
genase (type II) that is required for oxidation of NADH within
the cell (28).
In conclusion, our study shows that despite its down-regula-
tion during dormancy, ATP synthase plays an essential role for
mycobacterial survival and thus can serve as an ideal drug target
for killing dormant as well as actively replicating bacteria.
Unraveling the principles of energy metabolism during dor-
mancy and understanding the mechanisms of antibiotic action
can reveal critical weaknesses of dormant and persistent bacte-
rial species. In streptococci, ATP synthase was also found to be
differentially regulated in biofilm formation (32). The down-
regulation of F1F0-ATPase might make these bacteria more
susceptible to changes in cellular ATP pools. Thus, validating
ATP synthase as a target might also be useful to treat other
persistent bacterial infections.
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